Skip to main content
Grafa
Why medical imaging innovators are racing for regulatory clearance
Image for illustrative purposes only. Not a real photo.

Why medical imaging innovators are racing for regulatory clearance

Share
  • 4DMedical (ASX:4DX) secured Australian therapeutic approval for its non-contrast lung imaging software platform.
  • The affected software providers operate with contrasting financial profiles, ranging from $5.9 million to $628 million in annual revenues.
  • Securing government healthcare reimbursement and international commercial distribution models remains the primary strategy for the sector.

Here’s how other medical technology firms are trading after the approval

4DMedical (ASX:4DX)

The company announced that its non-contrast respiratory software, CT:VQ, received Australian regulatory clearance.

This platform extracts regional ventilation data from standard scans without requiring nuclear medicine infrastructure.

The firm generated $5.9 million in annual revenue alongside a net loss of $30.1 million.

Executives aim to progress an application for future national Medicare infrastructure reimbursement.

Pro Medicus (ASX:PME)

This enterprise health imaging provider designs visual software and radiology information systems.

The company reported an annual revenue increase of 31.9% to $213 million.

Management projects forward contracted revenues exceeding A$948 million over the next five years.

Mach7 Technologies (ASX:M7T)

This enterprise software provider delivers image data management and diagnostic viewing solutions to international healthcare networks.

The company reported total annual revenue of $33.8 million.

Executives project that internal cost-out initiatives will deliver $2–$3 million in annual savings.

Integral Diagnostics (ASX:IDX)

The corporation operates physical diagnostic clinics and medical imaging infrastructure across Australia and New Zealand.

The company recorded total annual revenue of $628 million. Net profit after tax concluded at $4.7 million for the reporting period.

The management team projects ongoing capital expenditures to modernise its regional clinic network.

IMEXHS (ASX:IME)

This medical technology firm manufactures cloud-based imaging software designed for international healthcare facilities.

The provider generated $29 million total revenue alongside a net loss of $2.9 million.

The business targets recurring subscription revenues through its core software distribution network.

The bottom line

The medical imaging ecosystem is shifting rapidly toward cloud software delivery and non-invasive diagnostic capabilities.

High-margin software providers like Pro Medicus demonstrate strong operating leverage, while developmental firms like 4DMedical consume capital to clear global regulatory hurdles.

Frequently asked questions